Back to Trials
NCT07231471NARecruitingAccepts Healthy Volunteers

Platelet Rich Plasma for Musculoskeletal Conditions

University of Utah

Start Date

12/29/2025

Completion Date

1/1/2035

Summary

The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction. This will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.

Detailed Description

Platelet-Rich Plasma (PRP) is an injectable preparation of a patient's blood that can be used for numerous conditions and has received significant attention over the past several years for its potential application for the treatment of pain and functional impairment due to osteoarthritis (OA) and other musculoskeletal conditions. Research on PRP has expanded dramatically over the last several decades, elevating its status from snake oil to a proven injection option superior to corticosteroids. It has demonstrated superior efficacy to standard-of-care corticosteroids in numerous musculoskeletal conditions. Systematic reviews of randomized-controlled trials have demonstrated equivalent-to-superior treatment outcomes associated with the use of intra-articular PRP compared to placebo, hyaluronic acid, and corticosteroid for the most commonly-studied condition, knee OA. Most importantly, just as corticosteroids have been used in numerous musculoskeletal conditions (OA, tendinopathy, bursitis, etc.), PRP has the same potential, but with vastly reduced risk; corticosteroids have many known dangers. To summarize, PRP has demonstrated level 1 evidence of superiority to corticosteroids in pain and function in numerous musculoskeletal conditions, with considerably less risk. This study will evaluate pain, function, and overall patient satisfaction outcomes for the use of PRP for the treatment of a diverse MSK conditions, including, but not limited to, OA of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * 18+ years old * Musculoskeletal pathology that may benefit from a PRP injection * Failed other conservative treatments Exclusion Criteria: * No active malignancy * No active infection in the area of injection * No platelet disorder * No active systemic infections * No patients currently undergoing dialysis

Interventions

BIOLOGICAL

Platelet Rich Plasma Injection

DEVICE

Platelet Rich Plasma Preparation

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Osteoarthritis (OA)Osteoarthritis (OA) of the KneeOsteoarthritis (OA) of the HipOsteoarthritis (OA) of the ShoulderOsteoarthritis AnkleElbow OsteoarthritisEpicondylitis of the ElbowPlantar Fasciitis of Both FeetTendinopathy

Locations

University of Utah Orthoaedic Center

Salt Lake City, Utah 84111-1334

United States